

## Mal-PEG8-Val-Ala-PAB-Exatecan


## Chemical Properties

CAS No. : 2679821-39-5

Formula: C<sub>66</sub>H<sub>85</sub>FN<sub>8</sub>O<sub>20</sub>

Molecular Weight: 1329.42

Storage: Keep away from moisture, Keep away from direct sunlight  
 Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Mal-PEG8-Val-Ala-PAB-Exatecan is an ADC linker-payload featuring a cathepsin B-cleavable Val-Ala linker and Exatecan. It is used for Nectin-4 targeted ADC development.
Targets(IC50)	Drug-Linker Conjugates for ADC, Nectin-4
In vivo	In KPL-4 xenograft models, conjugates with Mal-PEG8-Val-Ala-PAB-Exatecan (1-10 mg/kg) induced durable tumor regression and prolonged survival[1].

## Solubility Information

Solubility	DMSO: 80 mg/mL (60.18 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.7522 mL	3.761 mL	7.5221 mL
5 mM	0.1504 mL	0.7522 mL	1.5044 mL
10 mM	0.0752 mL	0.3761 mL	0.7522 mL
50 mM	0.015 mL	0.0752 mL	0.1504 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1 [J]. Clinical Cancer Research, 2016, 22(20): 5097-510

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481